BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matuszewska K, Pereira M, Petrik D, Lawler J, Petrik J. Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. Cancers (Basel) 2021;13:4444. [PMID: 34503254 DOI: 10.3390/cancers13174444] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Tang K, Fang R, Liu J, Liu M, Ma J, Wang H, Ding M, Wang X, Song Y, Yang D. Nanotechnological strategies to increase the oxygen content of the tumor. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1140362] [Reference Citation Analysis]
2 Zamborlin A, Voliani V. Gold nanoparticles as antiangiogenic and antimetastatic agents. Drug Discov Today 2023;28:103438. [PMID: 36375738 DOI: 10.1016/j.drudis.2022.103438] [Reference Citation Analysis]
3 Piao XM, Byun YJ, Zheng CM, Song SJ, Kang HW, Kim WT, Yun SJ. A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC. Cancers (Basel) 2023;15. [PMID: 36765892 DOI: 10.3390/cancers15030935] [Reference Citation Analysis]
4 Cai Y, Zang GY, Huang Y, Sun Z, Zhang LL, Qian YJ, Yuan W, Wang ZQ. Advances in neovascularization after diabetic ischemia. World J Diabetes 2022; 13(11): 926-939 [DOI: 10.4239/wjd.v13.i11.926] [Reference Citation Analysis]
5 Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer 2022;21:208. [PMID: 36324128 DOI: 10.1186/s12943-022-01670-1] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 He J, Liu Z, Zhu X, Xia H, Gao H, Lu J. Ultrasonic Microbubble Cavitation Enhanced Tissue Permeability and Drug Diffusion in Solid Tumor Therapy. Pharmaceutics 2022;14:1642. [PMID: 36015267 DOI: 10.3390/pharmaceutics14081642] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Fan P, Qiang H, Liu Z, Zhao Q, Wang Y, Liu T, Wang X, Chu T, Huang Y, Xu W, Qin S. Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front Immunol 2022;13:937924. [DOI: 10.3389/fimmu.2022.937924] [Reference Citation Analysis]
8 Dong H, Yang D, Hu Y, Song X. Recent advances in smart nanoplatforms for tumor non-interventional embolization therapy. J Nanobiotechnology 2022;20:337. [PMID: 35858896 DOI: 10.1186/s12951-022-01548-w] [Reference Citation Analysis]
9 Pereira M, Matuszewska K, Glogova A, Petrik J. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy. Cancers 2022;14:3500. [DOI: 10.3390/cancers14143500] [Reference Citation Analysis]
10 Li L, Li S, Fan Z, Huang G, Tang J, Nie L. Current Strategies of Photoacoustic Imaging Assisted Cancer Theragnostics toward Clinical Studies. ACS Photonics. [DOI: 10.1021/acsphotonics.2c00440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zeng Y, Yu T, Zhang S, Song G, Meng T, Yuan H, Hu F. Combination of tumor vessel normalization and immune checkpoint blockade for breast cancer treatment via multifunctional nanocomplexes. Biomater Sci 2022. [PMID: 35726757 DOI: 10.1039/d2bm00600f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Carmona-rodríguez L, Martínez-rey D, Martín-gonzález P, Franch M, Sorokin L, Mira E, Mañes S. Superoxide Dismutase-3 Downregulates Laminin α5 Expression in Tumor Endothelial Cells via the Inhibition of Nuclear Factor Kappa B Signaling. Cancers 2022;14:1226. [DOI: 10.3390/cancers14051226] [Reference Citation Analysis]
13 Kasherman L, Liu SL, Karakasis K, Lheureux S. Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers. Cancers (Basel) 2022;14:1122. [PMID: 35267430 DOI: 10.3390/cancers14051122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chen JM, Luo B, Ma R, Luo XX, Chen YS, Li Y. Lymphatic Endothelial Markers and Tumor Lymphangiogenesis Assessment in Human Breast Cancer. Diagnostics (Basel) 2021;12:4. [PMID: 35054174 DOI: 10.3390/diagnostics12010004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pereira M, Matuszewska K, Jamieson C, Petrik J. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer. Front Endocrinol (Lausanne) 2021;12:772349. [PMID: 34867818 DOI: 10.3389/fendo.2021.772349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]